GB2078755A - Oxytocin analogs and method for preparation thereof - Google Patents
Oxytocin analogs and method for preparation thereof Download PDFInfo
- Publication number
- GB2078755A GB2078755A GB8118815A GB8118815A GB2078755A GB 2078755 A GB2078755 A GB 2078755A GB 8118815 A GB8118815 A GB 8118815A GB 8118815 A GB8118815 A GB 8118815A GB 2078755 A GB2078755 A GB 2078755A
- Authority
- GB
- United Kingdom
- Prior art keywords
- oxytocin
- group
- amino
- deamino
- carba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 31
- 108700042417 deamino-6-carba- oxytocin Proteins 0.000 claims abstract description 20
- MRNKEVGKBFIFET-AHCPCVRLSA-N (2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(4s,7s,10s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carb Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 MRNKEVGKBFIFET-AHCPCVRLSA-N 0.000 claims abstract description 19
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 11
- 150000002148 esters Chemical class 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 26
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 101800000989 Oxytocin Proteins 0.000 abstract description 9
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 abstract description 9
- 229960001723 oxytocin Drugs 0.000 abstract description 9
- -1 ethoxy, amino, substituted amino Chemical group 0.000 abstract description 5
- QBETWIZYARXLPZ-YFKPBYRVSA-N (2s)-2-amino-4-(2-carboxyethylsulfanyl)butanoic acid Chemical group OC(=O)[C@@H](N)CCSCCC(O)=O QBETWIZYARXLPZ-YFKPBYRVSA-N 0.000 abstract description 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 17
- 229910001868 water Inorganic materials 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 102400000050 Oxytocin Human genes 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 238000002523 gelfiltration Methods 0.000 description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 7
- 235000011054 acetic acid Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001452 natriuretic effect Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ZEDBMCPXPIYJLW-XHNCKOQMSA-N Asp-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZEDBMCPXPIYJLW-XHNCKOQMSA-N 0.000 description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NQBGZEQVJIWSGT-INIZCTEOSA-N (2S)-2-anilino-3-(4-ethoxyphenyl)propanoic acid Chemical compound C1(=CC=CC=C1)N[C@@H](CC1=CC=C(C=C1)OCC)C(=O)O NQBGZEQVJIWSGT-INIZCTEOSA-N 0.000 description 1
- QCTLZQOZRYILCE-AWEZNQCLSA-N (2S)-3-(4-methyl-2-nitrophenyl)-2-(phenylsulfanylamino)propanoic acid Chemical compound [N+](=O)([O-])C1=C(C[C@H](NSC2=CC=CC=C2)C(=O)O)C=CC(=C1)C QCTLZQOZRYILCE-AWEZNQCLSA-N 0.000 description 1
- LVYWYLGWSVIFEV-ZDUSSCGKSA-N (2s)-3-(2-nitrophenyl)-2-(phenylsulfanylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NSC=1C=CC=CC=1)C1=CC=CC=C1[N+]([O-])=O LVYWYLGWSVIFEV-ZDUSSCGKSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- LHJGJYXLEPZJPM-UHFFFAOYSA-N 2,4,5-trichlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C=C1Cl LHJGJYXLEPZJPM-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GRDMQWRBLJZFML-UHFFFAOYSA-N bis(4-nitrophenyl) sulfite Chemical compound C1=CC([N+](=O)[O-])=CC=C1OS(=O)OC1=CC=C([N+]([O-])=O)C=C1 GRDMQWRBLJZFML-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001997 free-flow electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013080 microcrystalline material Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000000709 neurohypophysis hormone Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Analogs of oxytocin of general formula I <IMAGE> where all amino acids are L-isomers and X is phenylalanine or phenylalanine substituted in the p-position by alkyl, ethoxy, amino, substituted amino, or nitro group, suitable for medical applications, and a method for their preparation consisting in the cyclization of linear octapeptides of general formula II <IMAGE> where X has the aforesaid meaning and Act is a group activating the carboxylic group of S-carboxyethylhomocysteine residue, e.g. an active ester. Two methods may be used for the preparation of [2-p-aminophenylalanine] deamino-6-carba-oxytocin, either the reduction of [2-p-nitrophenylalanine]- deamino-6-carba-oxytocin or deprotection of [2-p- benzyloxycarbonylaminophenylalanine] deamino-6-carba-oxytocin.
Description
SPECIFICATION
Oxytocin analogs and method for preparation thereof
The invention relates to a method for the preparation of oxytocin analogs. More specifically, the present invention relates to a method for the preparation of deamino-6-carba-oxytocin having a modified amino acid in position 2, and to the oxytocin analogs so produced.
It has been recognized that some of the numerous activities of the neurohypophysial hormone oxytocin may be enhanced or suppressed by chemical modification of the molecule, and the attainment of biological effects is a condition precedent for its successful clinical application. Thus, for example, studies have revealed that replacement of a tyrosine group in the 2 position of a deamino-6carba-oxytocin molecule by a phenylalanine or a phenylalanine substituted in the para position yield compounds evidencing a high and specific natriuretic effect which may be suitable for use in treating renal and heart in-sufficiency or in some cases hypertension.
Workers in the art (Fraser, A.M. J. Pharmacol. Ex. Therapy 60, 89 (1937)) have long recognized that oxytocin evidences a natriuretic effect. Unfortunately, that effect is very weak and generally has superimposed thereon a strong antidiuretic activity. The deamino-6-carba-oxytocin evidences a substantially greater natriuretic effect and, even so, is combined with high values of other biological activities, such as oxytoxic, galactogogic and pressor activities, which preclude use of the natriuretic
effect of the compound in clinical applications. These analogs are not interesting only with respect to the absolute magnitude of natriuretic effect but also for specificity of the effect of the ratio of different
activities.
Moreover we cannot exclude apriori, that by different animals (including man), the value as well as specificy of the natriuretic effect can be different.
In accordance with the present invention, these prior art limitations are effectively obviated by
means of novel analogs of oxytocin of the general formula:
wherein the amino acids are of the L-series and X represents the amino acid phenylalanine or a phenylalanine substituted in the para position with a group selected from among alkyl, ethoxy, amino or substituted amino, or nitro groups.
The described novel oxytocin analogs (I) may be conveniently prepared by cyclization between an amino group of an amino acid X and the carboxylic group of the S-carboxyethylhomocysteine residue of a linear peptide of the general formula, (ill):
wherein X represents the amino acid phenylalanine or phenylalanine substituted in the para position by a group selected from among alkyl ethoxy, amino or substituted amine, or nitro groups and Act represents an activator for a carboxylic group such as an active ester group.
The analog of oxytocin of the following general formula, (III):
may conveniently be prepared either by (a) reduction of [2-p-nitrophenylalanine] deamino-6-carbaoxytocin with sodium in liquid ammonia or (b) from [2-p-benzyloxycarbonylaminophenylalanine deamino-6-carba-oxytocin by cleavage of the protecting group with hydrogen bromide in acetic acid.
Some biological activities of the analogs of oxytocin of general formula I are given in Table I in comparison to oxytocin.
TABLE I
Analogy I Biological Activity (in Rats)
Utero- Galacto- Natri
tonic gogic Pressor uretic
X (a) (a) (a) (b)
oxtytocin 450 450 3.0 100 NH-CH(CH2-QH)-C0 70 170 0.9 143
NH-CH(CH2-C6H4-CH3)CO 45 35 1 326 NH-CH(CH2-C8H4-C2H5)-CO 27 1.4 < 0.2 254 NH-CH(CH2-C6H4-0C2H)-C0 < 0.001 5.6 < 0.2 31
NH-CH(CH2-C6H4-NH2)-CO 15 7 < 0.2 87 NH-CH(0H2-C6H4-N(CH3)2)-CO < 0.14 4.5 < 0.2 75 NH-CH(CH2-C6H4-NH-CO2CH2.
.C6Hs)CO 0.07 < 0.2 10
NH-CH(CH2-C6H4 NO2) CO < 0.001 1.4 < 0.2 66 (a) International units per mg; (b) percent of oxytocin activity.
The method for producing the analogs of oxytocin is further illustrated in examples of performance:
EXAMPLE 1
This example described the preparation of [2-p-Nitro-phenylalanine] deam ino-6-carba-oxytocin.
Prior to the initiating of the preparation thereof, an octapeptide of formula II was prepared, as follows:
0.29 grams of 2,4,5-trichlorophenol and 0.33 grams of dicyclohexylcarbodiimide were added to a solution of ortho-nitrobenzenesulfenyl-para-nitrophenylalanine (0.53 grams) in a mixture of 1 5 cm3 of dichlorornethane and 1 5 cm3 of dimethylformamide cooled to -1 00C. The resultant mixture was stirred for one hour at-10 C and then for 12 hours at room temperature. Following, the mixture was concentrated in vacuum, resulting in the formation of crystals which were filtered by suction. The filter cake so produced was then washed with dichloromethane and the filtrate evaporated to dryness (at the 200C bath temperature). The yellow oil resulting was next triturated several times with petroleum ether and dissolved in 12 cm3 dimethylformamide.Following, the amide of isoleucyl-glutaminylasparaginyl-S-(2-carboxyethyl)homocysteinyl-prolyl-leucyl-glycine (0.8 g) was suspended in this solution and after stirring the resultant solution for 135 hours at ambient temperature it was evaporated to dryness (bath temperature 350C). The resultant oily product crystallized on trituration with petroleum
ether and was then successively washed on fritted glass with water, 0.05 M sulfuric acid, water and
ether, yielding 720 mg of an octapeptide melting within 215-219 C having the characteristics set forth in Table II, below:: TABLE II
Some characteristics of octapeptides of general formula
His RF
E
5.7 S1 S2
Gly Calculated Gly
E Molecular formula Found Asp Glu Pro Hcy (C2H4)
X 2.4 S3 S4 (Mol. weight) %C %H %N Ile Leu Xa COOH)
Phe(NO2) 0.14 0.37 0.07 C50H71B13O6S2. 61.15 6.09 15.51 1.05 1.04 1.05 1.07
0.57 0.49 0.62 (1174) 51.10 6.29 15.21 0.91 1.07 0.95 0.92
Phe(OEt) 0.14 0.36 0.07 C52H76N12O5S2. 52.03 6.63 14.00 1.07 1.02 1.07 1.03
0.56 0.48 0.62 1.5 H2O (1200) 51.97 6.55 12.98 0.92 1.07 0.96 0.85
Phe 0.10 0.40 0.17 C50H7N12O14S2. 50.72 6.64 14.19 1.05 1.01 1.01 1.04
0.66 0.49 0.65 3 H20 (1183) 50.69 6.38 14.31 0.93 1.02 0.95 0.99
Phe(NHZ) 0.11 0.47 0.19 C58H79N3O16S2. 53.00 6.36 13.85 1.07 1.06 0.98 1.08
0.65 0.57 0.69 2 H2O (1315) 53.03 6.45 14.09 0.93 1.10 0.86 0.89
Phe(Me) 0.11 0.35 0.07 C51H74N12O14S2. 52.74 6.60 14.47 1.04 1.10 0.87 1.06
0.68 0.49 0.66 H2O (1161) 52.75 6.67 14.66 0.91 1.05 1.03 0.95
Phe(Et) 0.09 0.48 0.10 C52H76N12O14S2. 52.34 6.76 14.08 1.00 1.02 0.99 1.01
0.61 0.41 0.69 2 H2O (1193) 52.48 6.50 13.81 0.90 1.01 1.00 0.84
Phe(NMe2) 0.21 0.11 0.06 C52H77N13O14S2. 51.69 6.75 15.07 1.08 1.01 1.10 1.06
0.96 0.10 0.66 2 H2O (1208) 51.81 6.56 14.98 1.00 1.07 0.74 0.84 aThe sum Tyr + Phe(OEt) is given for compounds containing Phe (OEt) ;
Phe(NH2) was determined for the compound containing Phe (NHZ).
Z=C6H5CH2OCO- 0.7 gram of bis(p-nitrophenyl) sulfite was then added to a solution of 200 milligrams of the
octapeptide so produced in 7 cm3 of dimethylformamide and 7 cm3 of pyridine through which nitrogen
had been bubbled. After stirring for 9 hours at room temperature, an additional 0.7 gram of sulfite was
added and after stirring for another 12 hours an additional 0.35 gram of sulfite was added. After 4
hours, the reaction mixture was concentrated in vacuum and the product precipitated by ether, filtered
by suction and thoroughly washed with ether. The product was then dried, dissolved in 7 cm3 of
dimethylformamide and 2.26 M hydrogen chloride in 0.52 cm3 of ether added thereto. The mixture so
obtained was permitted to stand for 7 minutes and diluted with 100 cm3 of ether.The hydrochloride precipitate of the compound of formula II was then filtered by suction, washed with ether and dried in
vacuum.
Cyclization to form a peptide bond was effected as follows: The hydrochloride prepared in the foregoing manner was dissolved in 7 cm3 of dimethylformamide and added at the rate of 2 cm3 Rer hour with a vigorously stirred mixture of 200 cm3 of pyridine and 50 microliters of N-ethylpiperidine which had nitrogen bubbled therethrough and which had been warmed to 500C. Following completion of the addition, the mixture was heated to 500C for 4 hours and permitted to stand at ambient temperature for 2 hours.Then, the solution was concentrated to a small volume (bath temperature -300C) and the product precipitated by ether. 1 70 mg of microcrystalline material were obtained. 100 mg of the product were then dissolved in 4 cm30 3 M acetic acid and applied on a column packed with polyacrylamide gel [Bio-gel-P-4(100 x 1 cm)]. Freeze-drying of the corresponding fractions yielded 70 mg of a compound which was again dissolved in 3 cm3 of 3 M acetic acid and applied on a column packed as above described. Freeze-drying of the corresponding fraction yielded 42 my of a compound.
1 5 mg of this product was dissolved in 2 cm3 of a methanol-water (2:3) mixture, and the solution applied on a column packed with modified silica gel (Separon SI-C18, 1 5 x 0.6 cm). Elution was then performed with a methanol-water mixture (44:56) ata pressure of 20 MPa. The fraction of k = 8.2 was concentrated in vacuum and freeze-dried, yielding 6.3 mg of the compound whose characteristics are set forth in Table Ill, on the following two pages.
EXAMPLE 2
This example describes the preparation of [2-para-ethoxyphenylalanine] deamino-6-carba-oxytocin.
The starting compound of formula II was prepared in the manner described in example 1. 0.23 gram of a suspension of the dicyclohexylammonium salt of ortho-nitrobenzenesul phenyl-p-ethoxyphenylalanin in
50 cm3 of ethyl acetate was then shaken with 0.05 M sulfuric acid and the resulting solution dried over sodium sulfate and evaporated to dryness. The oil so formed was then dissolved in dichloromethane and the active ester prepared in the manner described in example 1. Condensation with 0.25 gram of heptapeptide was performed in the same manner, yielding 200 mg of a compound having a melting point of 215-21 80C and evidencing characteristics of the type shown in Table II.
Next, the cyclization described in example 1 was conducted. The yield resulting from 200 mg of protected peptide was 196 mg of the product of cyclization. A part of the reaction mixture was purified by repeated gel filtration, yielding 8.3 mg of a pure compound evidencing the characteristics set forth in
Table Ill,ff: TABLE III
Some characteristics of cyclopeptides of general formula
RF Calculated
S1 S2 Molecular Found Gly
formula Asp Glu Pro Hcy
X S3 S4 (Mol. weight) %C %H %H Ile Leu Xa (C2H4COOH) k' sytemb
Phe(NO2) 0.19 0.13 C44H66N12O13S. 47.56 7.07 15.12 1.06 1.04 0.99 1.05 4.23 MeCH-H2O 1::1
0.24 0.65 6 H2O (1111) 47.58 6.63 14.80 0.95 1.04 0.89 0.95
Phe(OEt) 0.18 0.12 C45H71H11O12S. 53.51 7.10 13.73 1.07 1.04 0.94 1.00 2.27 MeOH-buffer pH
0.22 0.63 2 C2H4O2 (1122) 53.25 7.22 13.75 0.97 1.07 0.89 1.00 4.2 3:2
Phe 0.15 0.07 C44H67N11O11S. 53.15 7.20 15.50 0.96 1.01 1.02 0.97 7.00 MeOH-H2O 3:2
0.15 0.62 2 H2O (994.2) 52.90 6.95 15.26 0.97 1.06 1.01 1.01
Phe(NHZ) 0.33 0.12 C52H74H12O13S. 53.79 6.43 14.48 1.08 1.00 0.95 1.04 3.58 MeOH-buffer pH
0.21 0.62 3 H2O (1161) 53.95 6.32 14.30 0.92 1.00 0.82 1.00 4.2 3:2
Phe(Me) 0.28 0.14 C45H69H11O11S. 51.76 7.43 14.75 1.03 1.01 0.94 1.03 4.15 MeOH-buffer pH
0.23 0.69 4 H2O (1044) 51.89 7.15 14.73 0.96 1.05 1.08 0.90 4.4 3:2
Phe(Et) 0.27 0.14 C46H71H11O11S. 55.52 7.29 15.48 1.00 1.00 1.04 0.99 4.50 MeOH buffer pH
0.22 0.70 0.5 H2O (995.2) 56.03 7.33 15.08 0.97 1.00 1.09 0.96 4.4 13::7 TABLE III (Continued)
RF Calculated
S1 S2 Molecular Found Gly
formula Asp Glu Pro Hcy
X S3 S4 (Mol. weight) %C %H %H Ile Leu Xa (C2H4COOH) k' sytemb
Phe(NMe) 0.10 0.32 C46H72N12O11S. 53.28 7.00 16.21 1.09 1.04 1.09 1.04 2.62 MeOH-buffer pH
0.5 0.61 2 H2O (1037) 52.89 6.80 15.81 0.97 1.08 0.83 0.81 4.4 3:2
Phe(NH2) 0.08 0.05 C14H68N12O11S. 50.57 6.56 16.09 0.96 1.10 0.96 1.02 0.71 MeOH-buffer pH
0.05 0.57 4 H2O (1045) 50.90 6.39 15.70 1.03 1.12 0.79 0.95 4.4 3:2 a - The same meaning as in Table II.
b - The buffer of pH 4.2 is the 1% solution of trifluoroacetic acid with addition of triethylamine ;
the buffer of pH 4.4 is 0.015 M sodium phosphate.
EXAMPLE 3
This example describes the preparation of [2-phenylalaninet deamino-6-carba-oxytocin. The starting compound of formula II was prepared in the manner set forth in example 1. Then, 2,4,5trichlorophenyl ester of o-nitro-benzensulfenylphenylalanine was added to 0.8 gram of a suspension of free heptapeptide in 1 5 cm3 of dimethylformamide. After stirring for 96 hours at ambient temperature, the reaction mixture was treated as described in example 1. 1 gram (85%) of a compound having a melting point of 223-2250C was obtained, the characteristics thereof being set forth in Table II.
Cyclization was then performed as described in example 1. The product, which contained ninhydrin-positive material was dissolved in a 1:1 methanol water mixture and filtered through a column of sulfonate cation exchanger (Dowex 50 in the H+ cycle, 5 cm3). Concentration and freezedrying yielded 1 25 mg of a compound which was then purified by gel filtration. 1 5 mg of the product so obtained was then chromatographed on a column with modified silica gel (Separon SI C'8, 15 x 0.6 cm) in a 3:2 methanol water mixture. Concentration of the k = 7.0 fraction and freeze-drying yielded 4.2 mg of a compound, the characteristics of which are set forth in Table Ill.
EXAMPLE4 This example describes the preparation of [2-para-benzyloxycarbonylaminophenylalanine] deamino-6-carba-oxytocin. The starting compound was prepared (formula II) in the manner set forth in example 1. Ortho--nitrnbenzensulfenyl-para-benzyl-oxycarbonylaminophenylalanine was liberated from 1.05 grams of its dicyclohexylammonium salt in the manner described in example 2 and it was transferred into the active ester in the manner set forth in example 1.On trituration with petroleum ether, 1.0 gram of a crystalline compound was obtained having a melting point from 54--570C. The active ester (0.8 g) was added to a suspension of 0.6 gram of heptapeptide in 1 5 cm3 of dimethylformamide and processed as described in example 1.0.53 gram (55%) of a compound melting at 220-2220C was obtained having the characteristics set forth in Table II.
Cyclization was conducted as described in example 1, starting with 200 mug. 155 mg of a product was obtained and 30 mg thereof was purified by repeated gel fitration. Further refining was effected by chromatography on a column with reverse phase (modified silica gel Separon SI C18: 1 5 x 0.6 cm) in a mixture of methanol with trifluoroacetate buffer (3:2) of pH 4.4. The fraction containing the compound k
x 3.56 was freeze-dried and 4.2 mg of a product was obtained having the characteristics set forth in
Table ill.
EXAMPLE 5
This example describes the preparation of [para-aminophenylalanine] deamino-6-carba-oxytocin.
Sodium was added to 3.6 mg of a solution of [2-p-nitro-phenylalenine] deamino-6-carba-oxytocin in liquid ammonia (5 cm3) until a blue coloration which was stable for 30 seconds arose. Then, the solution was decolorized by addition of acetic acid and the residue, after evaporation of ammonia, was purified by gel filtration. The corresponding collected fractions gave by freeze-drying 2.1 mg of a compound which is characterized in Table ill.
EXAMPLE 6
A solution of hydrogen bromide in acetic acid (35% 1 cm3) was added to a suspension of [2-p benzyloxycarbonylaminophenylalaninej deamino-6-carba-oxytocin (30 mg) in acetone (1 cm3) and the solution formed was allowed to stand for 1 hour at ambient temperature. After repeated evaporation from acetone and reprecipitation from methanol with ether, the product was dissolved in 3 M acetic acid (3 cm3) and refined by gel filtration. Freeze-drying gave 8.7 mg of the compound which corresponded by its properties to the product according to Example 5.
EXAMPLE 7
This example describes the preparation of t2-p-methylphenylalanine] deamino-6-carba-oxytocin.
The active ester of o-nitrobenzenesulphenyl-p-methylphenylalanine was prepared from the corresponding dicyclohexylamonium salt (0.7 g) in the same manner as in Example 4. 0.58 gram of a compound melting at 127-1 33CC was obtained. This active ester was added to a suspension of heptapeptide (0.65 g) in dimethylformamide (13 cm3) and 0.83 g of a compound of m.p. 220-2260C was obtained in the same way as in example 1; the characteristics can be found in Table II.
Cyclization of 200 mg of peptide was carried out in the same way as in example 1. The product was obtained in the amount of 180 mg and a part of it (50 mg) was purified by gel filtration and a column chromatography (Separon SI C'8) in a mixture of methanol-water (3:2). The fraction of k = 5.03 yielded by freeze-drying 13.6 mg of the compound which is characterized in Table III.
EXAMPLE 8
This example described the preparation of [2-p-ethylphenylalanine] deamino-6-carba-oxytocin.
The protected octapeptide was prepared as described in example 1 from o-nitrobenzenesulphenyl-pethylphenylalanine (0.4 g) and the free heptapeptide (0.3 g). A compound melting 21 8-2240C was obtained in the amount of 0.23 g and its properties are given in Table II.
Cyclization and refining of the octapeptide were effected in the same manner as in example 7.
There was obtained 8.3 mg of the compound (k = 7.4, methanol-water (3:2) which exhibited properties shown in Table Ill.
EXAMPLE 9
This example describes the preparation of [2-p-dimethylaminophenylalaninej deamino-6-carbaoxytocin. The active ester of o-nitrobenzenesuíphenyl-p-dimethylaminophenylalanine was prepared from the dicyclohexylammonium salt (0.5 g) in the same manner as in example 4. A compound of m.p.
113-11 70C was obtained in the amount of 405 mg. This active ester was added to a suspension of heptatpeptide (0.3 g) in dimethylformamide and 0.43 g of a compound melting within the range of 201-2040C was obtained by the same procedure as in example 1 (omitting washing with diluted sulphuric acid). Its properties are shown in Table II.
Cyclization was carried out in the same way as in example 1 and yielded 190 mg of a product which was refined by gel filtration. The product obtained by freeze-drying (100 mg) was dissolved in 20% acetic acid and subjected to purification by free-flow electrophoresis. The compound obtained in the amount of 54 mg was further refined by gel filtration. Properties of the product (28 mg) are given in
Table ill.
Claims (7)
1. Oxytocin analogs of the general formula
wherein the designatedamino acids are of the L-series and X represents phenylalanine of phenylalanine substituted in the para position with a member selected from the group consisting of (a) alkyl groups, (b) ethoxy group, (c) amino group of substituted amino groups and (d) a nitro group.
2. Method for preparing oxytocin analogs in accordance with claim 1 which comprises cyclizing a linear peptide of the formula
wherein X represents an amino acid phenylalanine or phenylalanine substituted in the para position with a member selected from the group consisting of (a) alkyl group, (b) an ethoxy group, (c) an amino or substituted amino group, and (d) a nitro group; and Act represents a carboxyl group activator, the cyclization being effected between the amino group of amino acid X and the carboxyl group of Scarboxyethylhomocysteine residue.
3. A method for the preparation of a compound of the formula
which comprises reducing [2-p-nitrophenylalanine] deamino-6-carba-oxytocin with sodium in liquid ammonia.
4. Method in accordance with claim 2 wherein said activator is an ester.
5. Method in accordance with claim 3 wherein the protecting group is cleaved from [2-pbenzyloxycarbonylaminophenylalanine] deamino-6-carba-oxytocin by the action of hydrogen bromide in acetic acid.
6. An oxytocin analog as claimed in claim 1 substantially as described in any of the examples disclosed herein.
7. A method of preparing oxytocin analogs as claimed in claim 2 substantially as described herein.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS804465A CS216722B1 (en) | 1980-06-24 | 1980-06-24 | Oxytocine analogues and method of making the same |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2078755A true GB2078755A (en) | 1982-01-13 |
GB2078755B GB2078755B (en) | 1984-01-18 |
Family
ID=5387463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8118815A Expired GB2078755B (en) | 1980-06-24 | 1981-06-18 | Oxytocin analogues and method for preparation thereof |
Country Status (9)
Country | Link |
---|---|
JP (1) | JPS5753448A (en) |
CA (1) | CA1179328A (en) |
CH (1) | CH649090A5 (en) |
CS (1) | CS216722B1 (en) |
DE (1) | DE3124818A1 (en) |
FR (1) | FR2485527B1 (en) |
GB (1) | GB2078755B (en) |
IT (1) | IT1136670B (en) |
SE (1) | SE448303B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2526318A1 (en) * | 1982-05-10 | 1983-11-10 | Ceskoslovenska Akademie Ved | NEUROHYPOPHYSARY HORMONE ANALOGS HAVING INHIBITORY PROPERTIES |
EP0231077A2 (en) * | 1986-01-16 | 1987-08-05 | Smithkline Beckman Corporation | Polypeptide compounds |
US5225528A (en) * | 1990-02-27 | 1993-07-06 | Merck & Co., Inc. | Cyclic hexapeptide oxytocin antagonists |
CN111454333A (en) * | 2019-01-22 | 2020-07-28 | 南京济群医药科技股份有限公司 | Preparation method of high-purity oxytocin |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60198113A (en) * | 1984-03-21 | 1985-10-07 | 松下電器産業株式会社 | Juice squeezer of citrus fruits |
JPS60166706U (en) * | 1984-04-13 | 1985-11-06 | ナショナル住宅産業株式会社 | Fixed structure of exterior wall panels |
AT398767B (en) * | 1988-05-26 | 1995-01-25 | Gebro Broschek Gmbh | Process for the purification of a crude peptide by preparative medium pressure liquid chromatography |
TWI463990B (en) * | 2009-09-21 | 2014-12-11 | Ferring Bv | Oxytocin receptor agonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS194980B1 (en) * | 1976-07-16 | 1979-12-31 | Joseph H Cort | Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle |
-
1980
- 1980-06-24 CS CS804465A patent/CS216722B1/en unknown
-
1981
- 1981-06-16 SE SE8103778A patent/SE448303B/en not_active IP Right Cessation
- 1981-06-17 IT IT22390/81A patent/IT1136670B/en active
- 1981-06-18 GB GB8118815A patent/GB2078755B/en not_active Expired
- 1981-06-19 CH CH4086/81A patent/CH649090A5/en not_active IP Right Cessation
- 1981-06-23 CA CA000380428A patent/CA1179328A/en not_active Expired
- 1981-06-23 FR FR8112293A patent/FR2485527B1/en not_active Expired
- 1981-06-24 DE DE19813124818 patent/DE3124818A1/en not_active Withdrawn
- 1981-06-24 JP JP56098125A patent/JPS5753448A/en active Granted
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2526318A1 (en) * | 1982-05-10 | 1983-11-10 | Ceskoslovenska Akademie Ved | NEUROHYPOPHYSARY HORMONE ANALOGS HAVING INHIBITORY PROPERTIES |
EP0231077A2 (en) * | 1986-01-16 | 1987-08-05 | Smithkline Beckman Corporation | Polypeptide compounds |
EP0231077A3 (en) * | 1986-01-16 | 1989-06-07 | Smithkline Beckman Corporation | Polypeptide compounds |
US5225528A (en) * | 1990-02-27 | 1993-07-06 | Merck & Co., Inc. | Cyclic hexapeptide oxytocin antagonists |
CN111454333A (en) * | 2019-01-22 | 2020-07-28 | 南京济群医药科技股份有限公司 | Preparation method of high-purity oxytocin |
CN111454333B (en) * | 2019-01-22 | 2023-06-27 | 南京济群医药科技股份有限公司 | Preparation method of high-purity oxytocin |
Also Published As
Publication number | Publication date |
---|---|
JPS6330318B2 (en) | 1988-06-17 |
JPS5753448A (en) | 1982-03-30 |
FR2485527A1 (en) | 1981-12-31 |
SE8103778L (en) | 1981-12-25 |
SE448303B (en) | 1987-02-09 |
IT1136670B (en) | 1986-09-03 |
IT8122390A0 (en) | 1981-06-17 |
GB2078755B (en) | 1984-01-18 |
FR2485527B1 (en) | 1985-08-02 |
DE3124818A1 (en) | 1982-04-08 |
CS216722B1 (en) | 1982-11-26 |
CH649090A5 (en) | 1985-04-30 |
CA1179328A (en) | 1984-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5015728A (en) | Process for the preparation of insulin derivatives, the B chain of which is lengthened c-terminally | |
US4238481A (en) | Novel cyclopeptides | |
EP0021367B1 (en) | Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds | |
JPS60233098A (en) | Anticoagulant novel polypeptide | |
US3817973A (en) | Process for the preparation of cyclopeptides derived from polymyxins | |
KR0163224B1 (en) | Process for manufacture of 1-deamino-8-d-arginine vasopressin | |
Harris et al. | The synthesis of peptides related to gramicidin S and the significance of optical configuration in antibiotic peptides. 2. Pentapeptides | |
CA1315041C (en) | Methods and compositions for preparation of the tetrapeptide, alpha-t-x-omega-u-z-y-tyr-r' | |
FI79142C (en) | FOERFARANDE FOER FRAMSTAELLNING AV INSULINDERIVAT. | |
GB2078755A (en) | Oxytocin analogs and method for preparation thereof | |
US4275001A (en) | Process for the manufacture of LH-RH and LH-RH analogs using Glu-His(DnP)-OH | |
CA1246055A (en) | N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs | |
EP0394194B1 (en) | Protected amino-acids and process for their preparation | |
DE3884145T2 (en) | 4H-3,1-BENZOXAZINE-4-ON COMPOUNDS AND SERINE PROTEASE INHIBITING MEDICINAL PRODUCTS. | |
US3749703A (en) | Asn15-bovine thyrocalcitonin | |
CA2050929A1 (en) | Glutathione derivatives | |
US3076797A (en) | Process of producing oxytocin and intermediates obtained thereby | |
FR2557114A1 (en) | NOVEL DERIVATIVES OF GONADOLIBERIN, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
JPS62501501A (en) | Method for obtaining insulin precursor from the reaction mixture obtained during folding of insulin precursor from the corresponding S-sulfonate | |
CN106565771B (en) | Phosphorylcholine compound Lys-PC containing diamino and preparation method thereof | |
US3388112A (en) | Acth active peptides modified at the nu-terminal position | |
JPS58203982A (en) | Vitamin e-amino acid ester and its preparation | |
US3749704A (en) | N-(omega-amino lower alkyl)-amides of 1,17-modified acth peptides | |
US3272790A (en) | Polypeptides | |
US3280098A (en) | Process of producing peptides and products obtained thereby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |